Literature DB >> 28017799

X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B.

Christine A Vaine1, David Shin1, Christina Liu1, William T Hendriks1, Jyotsna Dhakal1, Kyle Shin1, Nutan Sharma2, D Cristopher Bragg3.   

Abstract

X-linked Dystonia-Parkinsonism (XDP) is a progressive neurodegenerative disease involving the loss of medium spiny neurons within the striatum. An XDP-specific haplotype has been identified, consisting of seven sequence variants which cluster around the human TAF1 gene, but a direct relationship between any of these variants and disease pathogenesis has not yet been demonstrated. Because the pathogenic gene lesion remains unclear, it has been difficult to predict cellular pathways which are affected in XDP cells. To address that issue, we assayed expression of defined gene sets in XDP vs. control fibroblasts to identify networks of functionally-related transcripts which may be dysregulated in XDP patient cells. That analysis derived a 51-gene signature distinguishing XDP vs. control fibroblasts which mapped strongly to nuclear factor-kappa B (NFκB), a transcription factor pathway also implicated in the pathogenesis of other neurodegenerative diseases, including Parkinson's (PD) and Huntington's disease (HD). Constitutive and TNFα-evoked NFκB signaling was further evaluated in XDP vs. control fibroblasts based on luciferase reporter activity, DNA binding of NFκB subunits, and endogenous target gene transcription. Compared to control cells, XDP fibroblasts exhibited decreased basal NFκB activity and decreased levels of the active NFκB p50 subunit, but increased target gene expression in response to TNFα. NFκB signaling was further examined in neural stem cells differentiated from XDP and control induced pluripotent stem cell (iPSC) lines, revealing a similar pattern of increased TNFα responses in the patient lines compared to controls. These data indicate that an NFκB signaling phenotype is present in both patient fibroblasts and neural stem cells, suggesting this pathway as a site of dysfunction in XDP. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DYT3; Fibroblasts; NFκB; NSCs; TAF1; XDP

Mesh:

Substances:

Year:  2016        PMID: 28017799      PMCID: PMC5316362          DOI: 10.1016/j.nbd.2016.12.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  103 in total

1.  Phenomenology of "Lubag" or X-linked dystonia-parkinsonism.

Authors:  Virgilio Gerald H Evidente; Joel Advincula; Raymund Esteban; Paul Pasco; Jhoe Anthony Alfon; Filipinas F Natividad; Joven Cuanang; Amado San Luis; Katrina Gwinn-Hardy; John Hardy; Dena Hernandez; Andrew Singleton
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

Review 2.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

3.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

Review 4.  Structural bioinformatics of the general transcription factor TFIID.

Authors:  Maja Malkowska; Katarzyna Kokoszynska; Leszek Rychlewski; Lucjan Wyrwicz
Journal:  Biochimie       Date:  2012-11-09       Impact factor: 4.079

5.  Interaction of TAFII105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes.

Authors:  A Yamit-Hezi; S Nir; O Wolstein; R Dikstein
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

6.  TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB.

Authors:  A Yamit-Hezi; R Dikstein
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

7.  Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50.

Authors:  F Driessler; K Venstrom; R Sabat; K Asadullah; A J Schottelius
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

Review 8.  NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review.

Authors:  Ruey-Horng Shih; Chen-Yu Wang; Chuen-Mao Yang
Journal:  Front Mol Neurosci       Date:  2015-12-18       Impact factor: 5.639

9.  Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells.

Authors:  Naoto Ito; William T Hendriks; Jyotsna Dhakal; Christine A Vaine; Christina Liu; David Shin; Kyle Shin; Noriko Wakabayashi-Ito; Marisela Dy; Trisha Multhaupt-Buell; Nutan Sharma; Xandra O Breakefield; D Cristopher Bragg
Journal:  Dis Model Mech       Date:  2016-01-14       Impact factor: 5.758

Review 10.  Transcriptional Control of Synaptic Plasticity by Transcription Factor NF-κB.

Authors:  Christian Engelmann; Ronny Haenold
Journal:  Neural Plast       Date:  2016-01-06       Impact factor: 3.599

View more
  2 in total

Review 1.  Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag).

Authors:  Toshitaka Kawarai; Ryoma Morigaki; Ryuji Kaji; Satoshi Goto
Journal:  Brain Sci       Date:  2017-06-26

2.  SVA insertion in X-linked Dystonia Parkinsonism alters histone H3 acetylation associated with TAF1 gene.

Authors:  Tiziana Petrozziello; Amanda M Dios; Kaly A Mueller; Christine A Vaine; William T Hendriks; Kelly E Glajch; Alexandra N Mills; Kotchaphorn Mangkalaphiban; Ellen B Penney; Naoto Ito; Cara Fernandez-Cerado; Gierold Paul A Legarda; M Salvie Velasco-Andrada; Patrick J Acuña; Mark A Ang; Edwin L Muñoz; Cid Czarina E Diesta; Regina Macalintal-Canlas; Geraldine Acuña; Nutan Sharma; Laurie J Ozelius; D Cristopher Bragg; Ghazaleh Sadri-Vakili
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.